benign-prostatic-hyperplasia
(2)
Shreya Mehta
Shreya Mehta is the President and CEO of Zenflow, a South San Francisco medical device company she co-founded in 2014 out of the Stanford Biodesign Innovation Fellowship. A biomedical engineer and former FDA reviewer, she spent a decade building the Zenflow Spring System, a minimally invasive, reversible implant that props open the urethra to relieve symptoms of benign prostatic hyperplasia (BPH). She started as CTO before stepping into the CEO seat, closed a $24M Series C in November 2024, and helped guide the company to FDA approval.
Zenflow, Inc.
Zenflow is a South San Francisco medical device company that built the Spring, a small nitinol coil implanted through a flexible cystoscope to prop open the urethra and relieve the symptoms of an enlarged prostate (benign prostatic hyperplasia). Spun out of Stanford's Biodesign program in 2014, the company won FDA approval in December 2025 for a first-line interventional therapy that requires no catheter afterward, preserves sexual function, and can be reversed. It has raised roughly $85 million across multiple rounds and ran the multinational BREEZE pivotal trial to get there.